Development and validation of a novel risk score to predict overall survival following surgical clearance of bilobar colorectal liver metastases

被引:0
|
作者
Dasari, Bobby V. M. [1 ,2 ,13 ]
Raptis, Dimitri [3 ]
Syn, Nicholas [4 ]
Serrablo, Alejandro [5 ]
Ramia, Jose Manuel [6 ]
Laurenzi, Andrea [7 ]
Sturesson, Christian [8 ,9 ]
Pawlik, Timothy M. [10 ]
Siriwardena, Ajith K. [11 ]
Lesurtel, Mickael [12 ]
Scientific Committee of E-AHPBA
机构
[1] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, England
[2] Queen Elizabeth Hosp, Dept HPB Surg & Liver Transplantat, Birmingham, England
[3] Royal Free Hosp, Dept HPB Surg & Liver Transplantat, London, England
[4] Natl Univ Singapore, Dept HPB Surg & Liver Transplantat, Singapore, Singapore
[5] Miguel Servet Univ Hosp, HBP Surg Div, Zaragoza, Spain
[6] Hosp Gen Univ Alicante, Dept Hepatobiliary Surg & Liver Transplantat, Alicante, Spain
[7] IRCCS Azienda Ospedaliero Univ Bologna, Hepatobiliary Surg & Organ Transplantat, Bologna, Italy
[8] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Surg, Stockholm, Sweden
[9] Karolinska Univ Hosp, Stockholm, Sweden
[10] Ohio State Univ, Wexner Med Ctr, Serv Management & Policy, Div Surg Oncol & Hlth, Columbus, OH USA
[11] Manchester Royal Infirm, Dept Hepatobiliary Surg, Manchester, England
[12] Univ Paris Cite, Beaujon Hosp, Dept HPB Surg & Liver Transplantat, Paris, France
[13] Queen Elizabeth Hosp, Dept HBP & Liver Transplantat Surg, Edgbaston, Birmingham B15 2TE, England
来源
BJS OPEN | 2023年 / 7卷 / 05期
关键词
TUMESCENT LOCAL-ANESTHESIA; BRACHIAL-PLEXUS BLOCK; OPTIMAL TIME-DELAY; DOUBLE-BLIND; SODIUM-BICARBONATE; DERMAL ARTERIES; NO TOURNIQUET; HAND SURGERY; NERVE BLOCK; EPINEPHRINE;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Bilobar liver metastases from colorectal cancer pose a challenge for obtaining a satisfactory oncological outcome with an adequate future liver remnant. This study aimed to assess the clinical and pathological determinants of overall survival and recurrence-free survival among patients undergoing surgical clearance of bilobar liver metastases from colorectal cancer.Methods A retrospective international multicentre study of patients who underwent surgery for bilobar liver metastases from colorectal cancer between January 2012 and December 2018 was conducted. Overall survival and recurrence-free survival at 1, 2, 3 and 5 years after surgery were the primary outcomes evaluated. The secondary outcomes were duration of postoperative hospital stay, and 90-day major morbidity and mortality rates. A prognostic nomogram was developed using covariates selected from a Cox proportional hazards regression model, and internally validated using a 3:1 random partition into derivation and validation cohorts.Results A total of 1236 patients were included from 70 centres. The majority (88 per cent) of the patients had synchronous liver metastases. Overall survival at 1, 2, 3 and 5 years was 86.4 per cent, 67.5 per cent, 52.6 per cent and 33.8 per cent, and the recurrence-free survival rates were 48.7 per cent, 26.6 per cent, 19.2 per cent and 10.5 per cent respectively. A total of 25 per cent of patients had recurrent disease within 6 months. Margin positivity and progressive disease at liver resection were poor prognostic factors, while adjuvant chemotherapy in margin-positive resections improved overall survival. The bilobar liver metastases from colorectal cancer-overall survival nomogram was developed from the derivation cohort based on pre- and postoperative factors. The nomogram's ability to forecast overall survival at 1, 2, 3 and 5 years was subsequently validated on the validation cohort and showed high accuracy (overall C-index = 0.742).Conclusion Despite the high recurrence rates, overall survival of patients undergoing surgical resection for bilobar liver metastases from colorectal cancer is encouraging. The novel bilobar liver metastases from colorectal cancer-overall survival nomogram helps in counselling and informed decision-making of patients planned for treatment of bilobar liver metastases from colorectal cancer. At a median follow-up of 50.9 months, the 1-year, 2-year, 3-year and 5-year overall survival rates were 86.4 per cent, 67.5 per cent, 52.6 per cent and 33.8 per cent respectively; the corresponding recurrence-free survival rates were 48.7 per cent, 26.6 per cent, 19.2 per cent and 10.5 per cent; the study demonstrates survival advantage of adjuvant chemotherapy in patients with margin-positive resection.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] 20 year survival after liver transplantation and development of a risk score to predict long term survival
    Bayer, J.
    McKenna, G. J.
    Onaca, N.
    Ruiz, R. M.
    Fernandez, H. T.
    Asrani, S. K.
    Klintmalm, G. B.
    Testa, G.
    TRANSPLANTATION, 2019, 103 (08) : 372 - 372
  • [32] Development and validation of survival nomograms in colorectal cancer patients with synchronous liver metastases underwent simultaneous surgical treatment of primary and metastatic lesions
    Guo, Xiao
    Liu, Yang
    Liu, Lu-Jia
    Li, Jun
    Zhao, Lei
    Jin, Xiang-Ren
    Yan, Wei
    Lin, Bai-Qiang
    Shi, Shang
    Li, Zhi-Yong
    Wang, Shuang
    Wu, Xin
    Chen, Hong-Ye
    Shen, Yang
    Wei, Yun-Wei
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 2654 - 2669
  • [33] Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation
    Goldaracena, Nicolas
    Mehta, Neil
    Scalera, Irene
    Sposito, Carlo
    Atenafu, Eshetu G.
    Yao, Francis Y.
    Muiesan, Paolo
    Mazzaferro, Vincenzo
    Sapisochin, Gonzalo
    HPB, 2019, 21 (06) : 731 - 738
  • [34] Development and validation of a prognostic score to predict the survival in adult patients with solid tumors and bone marrow metastases.
    Chou, Wen-Chi
    Peng, Mengting
    Liu, Chien-Ting
    Yeh, Kun-Yun
    Lu, Chang-Hsien
    Lin, Yung-Chang
    Liaw, Chuang-Chi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients with EGFR Mutant NSCLC
    Ng, I.
    Kumarakulasinghe, N.
    Syn, N.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S809 - S809
  • [36] Development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer
    Ye, Shu-Biao
    Cheng, Yi-Kan
    Hu, Jian-Cong
    Gao, Feng
    Lan, Ping
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (04)
  • [37] The impact of recurrence timing and tumor burden score on overall survival among patients undergoing repeat hepatectomy for colorectal liver metastases
    Endo, Yutaka
    Rueda, Belisario Ortiz
    Woldesenbet, Selamawit
    Munir, Muhammad Musaab
    Lima, Henrique A.
    Katayama, Erryk S.
    Shaikh, Chanza F.
    Guglielmi, Alfredo
    Ruzzenente, Andrea
    Aldrighetti, Luca
    Alexandrescu, Sorin
    Kitago, Minoru
    Poultsides, George
    Sasaki, Kazunari
    Aucejo, Federico
    Pawlik, Timothy M.
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (04) : 560 - 568
  • [38] Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis
    Chen, Feng-Lin
    Wang, Yan-Yan
    Liu, Wei
    Xing, Bao-Cai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Preoperative FDG-PET-Scan in Patients with Resectable Colorectal Liver Metastases Does Not Improve Overall Survival: A Retrospective Analyses Stratified by Clinical Risk Score
    Ayez, N.
    de Ridder, J.
    Wiering, B.
    Oyen, W. J.
    de Wilt, J. H. W.
    Verhoef, C.
    DIGESTIVE SURGERY, 2013, 30 (4-6) : 451 - 458
  • [40] Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease
    Li, Ning
    Zhou, Guowei
    Zheng, Yawei
    Zhou, Enchao
    He, Weiming
    Sun, Wei
    Zhang, Lu
    RENAL FAILURE, 2022, 44 (01) : 241 - 249